![]() |
![]() |
![]() |
2024-08-13 :
The use of chondroprotectors in patients with osteoarthritis in combination with goutSummary. According to research data, the problem of osteoarthritis (OA) is increasing due to a high level of comorbidity — in 69.0% — 98.0% of patients, including patients with gout arthritis (GA), whose pathogenesis is based on an inflammatory process. The comorbidity of OA with GA affects the clinical picture of both diseases and worsens the quality of life of patients, and therefore requires a personalized approach to the selection of drug therapy. The purpose of the study: the choice of chondroprotective therapy in patients with OA and GA. Research methods. All OA and GA patients were evaluated and diagnosed according to Wallace S. 1977 diagnostic criteria for gout and American College of Rheumatology (ACR) 2010 diagnostic criteria for osteoarthritis. Diagnostic methods of OA and GA: x-ray and ultrasound of joints, pain assessment according to the VAS scale, assessment of quality of life according to the EuroQol-5D questionnaire, algofunctional Leken index. Laboratory studies included determining the level of uric acid (UA), serum glucose level, control of liver and kidney function according to the level of alanine transaminase (ALT) and aspartate transaminase (AST), endogenous creatinine, urea. The establishment of an immunoinflammatory reaction was carried out by determining the level of TNF-α, IL-6 using standard sets of reagents by the solid-phase immunoenzymatic method. Results. 50 patients were examined (30 for OA and 20 for GA). As a result of the study, it was found that patients with OA in combination with GA had more pronounced violations of clinical indices, more severe manifestations of synovitis and degenerative changes in the knee joints compared to patients without GA. Conclusion. Osteoarthritis is quite often diagnosed in patients with gout, as they share common pathogenetic mechanisms and influence the course, severity of the disease, and treatment approaches. The chondroprotective drug Protekon in complex treatment contributed to the rapid reduction of pain syndrome, suppression of the inflammatory process in the joints, and slowing down of degenerative processes. No Comments » Add your |
||
Leave a comment